Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned an average recommendation of “Hold” from the twenty ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $71.08.

A number of analysts have recently weighed in on the stock. Stifel Nicolaus reissued a “buy” rating and set a $85.00 price target (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. JMP Securities decreased their price target on shares of Ultragenyx Pharmaceutical from $90.00 to $80.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 23rd. Leerink Swann reissued an “outperform” rating and set a $83.00 price target (down previously from $89.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Jefferies Group LLC set a $62.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a “hold” rating in a research report on Wednesday, August 23rd. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $69.00 price objective (down previously from $80.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $47.41 on Monday. Ultragenyx Pharmaceutical has a 1 year low of $44.45 and a 1 year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.87). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. During the same period in the previous year, the business posted ($1.64) EPS. The firm’s quarterly revenue was up 81.8% compared to the same quarter last year. equities research analysts predict that Ultragenyx Pharmaceutical will post -7.24 earnings per share for the current year.

In related news, CEO Emil D. Kakkis acquired 7,500 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The shares were acquired at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the completion of the purchase, the chief executive officer now directly owns 430,569 shares in the company, valued at $22,613,483.88. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 9.20% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of RARE. Prudential Financial Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 5.8% during the first quarter. Prudential Financial Inc. now owns 3,660 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 200 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Ultragenyx Pharmaceutical by 3.3% during the first quarter. Teachers Advisors LLC now owns 163,898 shares of the biopharmaceutical company’s stock valued at $11,109,000 after purchasing an additional 5,203 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Ultragenyx Pharmaceutical by 3.6% during the first quarter. Legal & General Group Plc now owns 12,870 shares of the biopharmaceutical company’s stock valued at $870,000 after purchasing an additional 448 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 5.7% during the first quarter. Vanguard Group Inc. now owns 2,994,938 shares of the biopharmaceutical company’s stock valued at $202,997,000 after purchasing an additional 161,622 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Ultragenyx Pharmaceutical by 51.6% during the first quarter. Dimensional Fund Advisors LP now owns 17,092 shares of the biopharmaceutical company’s stock valued at $1,158,000 after purchasing an additional 5,816 shares in the last quarter. Institutional investors and hedge funds own 95.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Ultragenyx Pharmaceutical Inc. (RARE) Receives Consensus Rating of “Hold” from Brokerages” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/11/13/ultragenyx-pharmaceutical-inc-rare-receives-consensus-rating-of-hold-from-brokerages.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.